In a recent issue of CHEST (January 2015), Davidson 1 commented on the association between direct thrombin inhibitors, including bivalirudin, ximelagatran, and dabigatran, and cardiac thrombosis. He concludes that the guilt [of these substances in causing cardiac thrombosis] appears undeniable and that clinicians should avoid prescribing direct thrombin inhibitors. Th is statement is based on a rather one-sided thought process and warrants a more balanced view based on a careful review of the current knowledge, particularly with respect to the use of dabigatran. Th e major indication for this drug is stroke prevention in atrial fi brillation (AF) for which it has been approved since 2009. Hence, our response focuses on dabigatran in patients with AF.
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Dabigatran and Myocardial Infarction
To the Editor:
In a recent issue of CHEST (January 2015), Davidson 1 commented on the association between direct thrombin inhibitors, including bivalirudin, ximelagatran, and dabigatran, and cardiac thrombosis. He concludes that the guilt [of these substances in causing cardiac thrombosis] appears undeniable and that clinicians should avoid prescribing direct thrombin inhibitors. Th is statement is based on a rather one-sided thought process and warrants a more balanced view based on a careful review of the current knowledge, particularly with respect to the use of dabigatran. Th e major indication for this drug is stroke prevention in atrial fi brillation (AF) for which it has been approved since 2009. Hence, our response focuses on dabigatran in patients with AF.
In the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial, there were numerically more myocardial infarctions (MIs) in patients taking dabigatran (0.8%/y) than in those taking warfarin (0.6%/y), but this fi nding was nonsignifi cant. Th e absolute diff erence in rates of new MIs was extremely low (0.2%/y), limiting statistical power for any comparison. In a post hoc analysis of the RE-LY trial, a variety of other ischemiarelated outcomes were similar between treatment groups. 2 An estimation of the net clinical benefi t indicated a signifi cant diff erence in favor of dabigatran.
Several real-world datasets have been published evaluating the benefi ts and risks of dabigatran. In a nationwide Danish registry study, 4,978 incident dabigatran users were propensity matched to 8,936 users of warfarin. 3 Rates for stroke, peripheral embolism, and major bleeding were similar for dabigatran and warfarin. However, mortality, intracranial bleeding, and MI events were lower with dabigatran. The unadjusted hazard ratio (HR) for MI for dabigatran 110 mg bid vs warfarin was 0.60 (95% CI, 0.33-1.02) and for dabigatran 150 mg bid vs warfarin, 0.62 (95% CI, 0.30-1.14). Th e largest study on dabigatran 150 mg was published by the US Food and Drug Administration, 4 Th eir defense of dabigatran for atrial fi brillation, ie, that increased MIs do not matter in the big picture, uses questionable observations from large registries to refute hard evidence from patients under surveillance in randomized studies. Th e Danish registry study 1 of Dr Lip and colleagues cannot support their claim. Th eir report states that MI was not predefi ned as either a primary or secondary outcome; they studied only new users; their patients were far less sick than those in the clinical trials; they followed patients for , 18 months; few patients with moderate/severe renal or liver disease received dabigatran; and so forth.
Th e bias in the US Food and Drug Administration Medicare dataset 2 is that US patients using dabigatran are, on average, likely to be wealthier, hence less sick, than patients taking warfarin. Th e patients taking dabigatran in the Medicare dataset mostly pay extra for Medicare-plus insurance and still aff ord about $40/mo more just for dabigatran; poorer Medicare-only patients pay $4/mo (or less) for warfarin (international normalized ratios and clinic visits are free). Th e groups are socioeconomically dissimilar, and MIs are not diligently looked for as they were in the clinical trials that led the sponsor of dabigatran to conclude that dabigatran is associated with more MIs than well-controlled warfarin, as cited in my commentary 3 and in the US Food and Drug Administration-approved dabigatran drug label. It is diffi cult to consider any of these revised series of event numbers as robust. 6 , 7 Th e doctors' comment about statistically insignifi cant higher numerical rates of MI associated with diff erent oral anti-Xa anticoagulants pertains to subsets of patients receiving a low dose and populations from selected continents. Unlike the repeatedly confi rmed, significantly higher rate of MIs associated with direct thrombin inhibitors compared with warfarin, there is still not the fi rst piece of randomized trial evidence for such an association with anti-Xa anticoagulants. To reiterate: Other than in exceptional circumstances, clinicians should prescribe eff ective anticoagulants other than direct thrombin inhibitors.
